GlassScriptPhysician profile
Irina Pruchansky
NPI 1811080351
$7,021.50
in general payments reported to CMS, 2019-2025
39 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $826 · 2021: $1,275 · 2022: $1,084 · 2023: $760 · 2024: $892 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,780.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,440.73 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,038.85 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Novo Nordisk INC | $711.10 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $688.90 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $272.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $258.03 | 2020-2021 | |
| Lilly USA, LLC | $225.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $208.79 | 2019-2022 | |
| Amgen INC. | $187.87 | 2019-2025 | Repatha, Otezla, Repatha |
| Ironwood Pharmaceuticals, INC | $165.73 | 2021-2024 | Linzess |
| Azurity Pharmaceuticals, INC. | $150.52 | 2023-2025 | Konvomep, Alvesco, Horizant |
| Amarin Pharma, INC. | $149.68 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $132.11 | 2019-2021 | |
| Medtronic, INC. | $127.23 | 2022 | |
| Allergan, INC. | $122.22 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irina Pruchansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.